Calendario›REGN›Garetosmab

Garetosmab

Study of Safety and Effects of Garetosmab in Healthy Obese Men and Post-Menopausal Women

Ensayo de REGENERON PHARMACEUTICALS, INC. en Obesidad.

Más ensayos de: Obesidad.

Fase

Fase 1

Estado

Retirado antes de empezar

Fin del objetivo primario

jun 2026

estimado por el promotor

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, triple ciego. Comenzó en may 2025.

Este ensayo se detuvo. Motivo declarado por el promotor (del registro, en inglés): «Sponsor Decision».

Qué mide

Incidence of treatment-emergent adverse events (TEAEs) (Through Week 32) (del registro, en inglés)

Cómo lo describe el promotor

En el documentoEn inglés, del registroThis study is researching an experimental drug called garetosmab, referred to as "study drug". The study is focused on otherwise healthy participants with obesity. The aim of the study is to see how safe and tolerable the study drug is. The study is looking at several other research questions, including: * How much study drug is in the blood at different times * What effect the study drug has on the blood clotting * What effect the study drug has on hormone levels * What effect the study drug has on some organs that produce hormones * What effect hormones have on the side effects produced by the study drug * Whether the body makes antibodies against the study drug (which could change how well the drug works or could lead to side effects)

Más ensayos de REGN

Todos los de REGN, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT06970405), actualizada en sep 2025.